You are here

Article info

Article menu
Clinical/translational cancer immunotherapy
Original research
Activin-A impairs CD8 T cell-mediated immunity and immune checkpoint therapy response in melanoma

Authors

  • Katarina Pinjusic School of Life Sciences (SV), ISREC, Ecole Polytechnique Federale de Lausanne, Lausanne, Switzerland PubMed articlesGoogle scholar articles
  • Olivier Andreas Dubey School of Life Sciences (SV), ISREC, Ecole Polytechnique Federale de Lausanne, Lausanne, Switzerland PubMed articlesGoogle scholar articles
  • Olga Egorova School of Life Sciences (SV), ISREC, Ecole Polytechnique Federale de Lausanne, Lausanne, Switzerland PubMed articlesGoogle scholar articles
  • Sina Nassiri Bioinformatics Core Facility, Swiss Institute of Bioinformatics, Lausanne, Switzerland PubMed articlesGoogle scholar articles
  • Etienne Meylan School of Life Sciences (SV), ISREC, Ecole Polytechnique Federale de Lausanne, Lausanne, SwitzerlandLaboratory of Immuno-Oncology, Bordet Cancer Research Laboratories, Institut Jules Bordet, Faculty of Medicine, and Laboratory of Immunobiology, Faculty of Sciences, Université Libre de Bruxelles, Bruxelles, Belgium PubMed articlesGoogle scholar articles
  • Julien Faget School of Life Sciences (SV), ISREC, Ecole Polytechnique Federale de Lausanne, Lausanne, SwitzerlandEquipe Immunity and Cancer IRCM, INSERM U1194, Montpellier, France PubMed articlesGoogle scholar articles
  • Daniel Beat Constam School of Life Sciences (SV), ISREC, Ecole Polytechnique Federale de Lausanne, Lausanne, Switzerland PubMed articlesGoogle scholar articles

Citation

Pinjusic K, Dubey OA, Egorova O, et al
Activin-A impairs CD8 T cell-mediated immunity and immune checkpoint therapy response in melanoma
Journal for ImmunoTherapy of Cancer 2022;10:e004533. doi: 10.1136/jitc-2022-004533
Online issue publication 
May 17, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See https://creativecommons.org/licenses/by/4.0/.